Vista Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Vista Pharmaceuticals's earnings have been declining at an average annual rate of -40.9%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been declining at an average rate of 60.4% per year.
Key information
-40.9%
Earnings growth rate
-34.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -60.4% |
| Return on equity | -22.0% |
| Net Margin | -103.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Vista Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 82 | -85 | 16 | 0 |
| 30 Sep 23 | 65 | -78 | 13 | 0 |
| 30 Jun 23 | 30 | -62 | 9 | 0 |
| 31 Mar 23 | 10 | -57 | 5 | 0 |
| 31 Dec 22 | 0 | -13 | 5 | 0 |
| 30 Sep 22 | 1 | 6 | 4 | 0 |
| 30 Jun 22 | 4 | -13 | 4 | 0 |
| 31 Mar 22 | 4 | -9 | 7 | 0 |
| 31 Dec 21 | 9 | -16 | 10 | 0 |
| 30 Sep 21 | 11 | -31 | 12 | 0 |
| 30 Jun 21 | 13 | -17 | 14 | 0 |
| 31 Mar 21 | 13 | -20 | 12 | 0 |
| 31 Dec 20 | 16 | -52 | 12 | 0 |
| 30 Sep 20 | 86 | -50 | 11 | 0 |
| 30 Jun 20 | 163 | -41 | 11 | 0 |
| 31 Mar 20 | 228 | -37 | 16 | 0 |
| 31 Dec 19 | 341 | 6 | 16 | 0 |
| 30 Sep 19 | 344 | 9 | 15 | 0 |
| 30 Jun 19 | 322 | 9 | 14 | 0 |
| 31 Mar 19 | 311 | 9 | 15 | 0 |
| 31 Dec 18 | 267 | 9 | 15 | 0 |
| 30 Sep 18 | 268 | 14 | 14 | 0 |
| 30 Jun 18 | 276 | 19 | 13 | 0 |
| 31 Mar 18 | 289 | 22 | 12 | 0 |
| 31 Dec 17 | 273 | 17 | 44 | 0 |
| 30 Sep 17 | 265 | 15 | 43 | 0 |
| 30 Jun 17 | 257 | 12 | 43 | 0 |
| 31 Mar 17 | 242 | 12 | 10 | 0 |
| 31 Dec 16 | 239 | 47 | 21 | 0 |
| 30 Sep 16 | 224 | 31 | 20 | 0 |
| 30 Jun 16 | 198 | 16 | 20 | 0 |
| 31 Mar 16 | 154 | 8 | 20 | 0 |
| 31 Dec 15 | 121 | -26 | 19 | 0 |
| 30 Sep 15 | 123 | -6 | 21 | 0 |
| 30 Jun 15 | 121 | 8 | 21 | 0 |
| 31 Mar 15 | 137 | 14 | 21 | 0 |
| 31 Dec 14 | 167 | 23 | 13 | 0 |
| 30 Sep 14 | 116 | 11 | 11 | 0 |
| 30 Jun 14 | 105 | 9 | 6 | 0 |
| 31 Mar 14 | 83 | 5 | 12 | 0 |
| 31 Dec 13 | 46 | -9 | 10 | 1 |
| 30 Sep 13 | 64 | -3 | 11 | 1 |
| 30 Jun 13 | 62 | -3 | 11 | 1 |
Quality Earnings: 524711 is currently unprofitable.
Growing Profit Margin: 524711 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524711 is unprofitable, and losses have increased over the past 5 years at a rate of 40.9% per year.
Accelerating Growth: Unable to compare 524711's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 524711 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 524711 has a negative Return on Equity (-21.97%), as it is currently unprofitable.